Aktuellt
SENASTE
Redeye leaves an initial comment following the Q2 report published by Magle this morning. The second quarter of 2024 for Magle was primarily marked by the merger and acquisitions of Amniotics and pK Chemicals. We believe that both of these are poised to generate long-term shareholder value for Magle. Beyond that, the company reported a slightly higher sales figure than expected, a 21% y/y growth, with an increase in revenue from its DSM products. However, as OPEX and COGS came in above our expectations, this resulted in a lower EBIT than expected.
LÄS MER
